Laurus Lab Results Analysis

In March-25 (Q4-2025) Results, Company shown 19% increase in Revenue and 210% Increase in PAT on YoY basis. For Complete F.Y. 2025 Company shown 10.2% increase in Revenue, primarily driven by strong CDMO execution while generic FDF growth offset by lower API business, EBITDA Margins : 20.1%, increased 430 bps YoY, due to improving revenue delivery and gradual step up in asset utilization and 120.99% Increase in PAT on YoY basis. In Q4 FY25, EBITDA increased by 84% to 477 Cr. on YoY basis. In Q4 FY25,,EBITDA Margin was 27.7%, improved by 970 basis points on YoY basis, due to improving revenue delivery and strong operating leverage. FY25 CAPEX at ₹ 659 Cr, CDMO capacity expansion completed across multiple sites in 2025 along w/new CDMO R&D, AH MB-3 & Bio pilot facility. Corp-science facility started operations in Q4.